Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

NUTLEY, N.J., Jan. 14 /PRNewswire/ -- Following an announcement from Schering-Plough, Roche today affirmed the value of PEGASYS(R) (peginterferon alfa-2a) in combination with ribavirin as the market-leading treatment for patients with hepatitis C, in the United States and globally. Despite clear biases in the design of the "IDEAL" study that potentially favored patients taking Peg-Intron(TM) (peginterferon alfa-2b) regimens - particularly the ribavirin dose reduction protocol - the study results have shown that patients treated with a PEGASYS regimen had a similar chance of being successfully treated for hepatitis C.

"I do not expect that the results of the IDEAL study will meaningfully impact clinical practice, except to inform physicians on the appropriate dosing of Peg-Intron and to reinforce the already widely-accepted view that optimizing ribavirin dosing throughout treatment is critical to achieving success and preventing treatment relapse in hepatitis C," said Douglas Dieterich, M.D., Professor of Medicine in the Division of Hepatology at Mt. Sinai School of Medicine in New York, New York.

In 2001, the U.S. Food and Drug Administration (FDA) required Schering- Plough to conduct a post approval commitment trial to determine if a lower dose of Peg-Intron (1.0 mcg/kg) was as effective as the approved dose of 1.5 mcg/kg, both in combination with identical ribavirin regimens. A third arm was added to the study in which patients received PEGASYS 180 mcg with a different ribavirin dosing schedule. This mismatch of ribavirin dosing introduces several potential biases into the study because experts agree that an optimized dose of ribavirin, with either pegylated interferon, is critical to achieving success in hepatitis C treatment. In particular, maintaining a full dose of ribavirin has shown an important ability to reduce relapse following the end of treatment.

"PEGASYS quickly became the market leader after its launch, based on robust cli
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... CorMatrix® Cardiovascular, a medical device company dedicated to developing ... body,s innate ability to repair damaged cardiovascular tissue, announced today it ... Repair. With this designation, CorMatrix is now able to market this ... , , ...
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and CFO ... Global Healthcare Conference on Tuesday, June 15 , at 3:05 ... Los Angeles .  The presentation will be webcast on the following link: ... , Perrigo ...
Cached Medicine Technology:CorMatrix(R) ECM(TM) Receives CE Mark for Cardiac Tissue Repair 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... risk of death and heart attack can be reduced for ... the usual dose of an anti-clotting drug before the procedure ... a balloon-tipped catheter is threaded into an artery. The balloon ... the vessel. A small synthetic tube - stent is used ...
... It has been found out that there is no association ... food -- and breast cancer. More than 43,000 women were ... participants had their average daily intake of acrylamide monitored. No ... women whose intake was higher was documented. Acrylamide was first ...
... Session of the International Association for Dental Research held ... of a study// that says eating sugar-free yogurt is ... bad odor or so called bad breath is caused ... The study revealed that volunteers who had sugar-free more ...
... has found out that depression has to be blamed for ... to treat the same. The study was conducted on 60,000 ... results showed both the newer and older classes of antidepressants ... first month of being prescribed.The older class of tricyclic antidepressants ...
... of the drug tezosentan did not improve worsening heart failure ... despite high hopes. The above fact was found out in ... The study was conducted to evaluate if something more could ... speed up hospital discharge and prevent them from coming back. ...
... known to help in controlling obesity. A new study coming ... (2005) says that dietary calcium present in the yogurt has ... lipid utilization and decrease in lipogenesis. ,The ... group was put on balanced deficit diets and the other ...
Cached Medicine News:
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Ballard trach care HMES and filters, universal use, "Y" filter, CO 2 sampling port...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
Medicine Products: